INDP
Indaptus Therapeutics, Inc. (INDP) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Liquidity is exceptionally strong with a 19.5x current and quick ratio, giving INDP more near-term funding flexibility than most peers.
Net debt to EBITDA of 0.49x indicates modest leverage, so balance-sheet risk is lower than for more indebted small-cap industrial peers.
Cash conversion cycle at 0 suggests working-capital discipline, which supports operating resilience relative to peers with longer cash cycles.
Weaknesses
ROIC of -1.3% shows capital is still destroying value, leaving INDP structurally behind profitable peers on long-term returns.
The absence of positive margin disclosure alongside negative ROIC implies weak earnings quality, which limits peer-relative operating strength.
A zero debt-to-equity reading may reflect limited balance-sheet leverage data rather than strength, while peers with proven profitability remain structurally superior.
Opportunities
If management converts excess liquidity into higher-return assets, INDP can narrow the gap versus peers with stronger reinvestment economics.
A low leverage profile leaves room to fund growth or restructuring more flexibly than peers already constrained by heavier debt loads.
Working-capital efficiency can support incremental scale-up, which would matter more if peers face tighter cash discipline in the same market.
Threats
Persistent negative ROIC raises the risk that peers with positive returns will compound faster and widen the structural performance gap.
Without visible margin strength, INDP remains exposed to pricing pressure and cost inflation relative to peers with better operating leverage.
If liquidity is used to offset losses rather than fund durable growth, the company could lag peers that convert capital into earnings more efficiently.
Overall Score
INDP’s balance sheet is liquid and lightly levered, but persistent value destruction and limited operating evidence leave it structurally weaker than stronger peers.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Indaptus Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
